BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Galderma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Galderma's drugs run\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07074977-1524@assetmemo.bio
DTSTAMP:20261121T005559Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nemluvio (nemolizumab): Phase 2 readout est. (NCT07074977)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 2.\nStudy: Proof of Concept Stud
 y to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults
  With Chronic Pruritus of Unknown Origin (CPUO)\nEstimated primary complet
 ion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 emolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07074977
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762833-1524@assetmemo.bio
DTSTAMP:20261121T005559Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Nemluvio (nemolizumab): Phase 3 readout est. (NCT07762833)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 3\, Atopic Dermatitis.\nStudy: R
 andomized\, Double-blind\, Placebo-controlled Study of Nemolizumab in Chin
 ese Subjects With Moderate-to-severe Atopic Dermatitis\nEstimated primary 
 completion: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nemolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07762833
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047690-1524@assetmemo.bio
DTSTAMP:20261121T005559Z
DTSTART;VALUE=DATE:20280528
DTEND;VALUE=DATE:20280529
SUMMARY:Nemluvio (nemolizumab): Phase 2 readout est. (NCT07047690)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 2.\nStudy: A Study of Nemolizuma
 b for the Treatment of Adults With Systemic Sclerosis\nEstimated primary c
 ompletion: 28 May 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/nemolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07047690
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07660835-1524@assetmemo.bio
DTSTAMP:20261121T005559Z
DTSTART;VALUE=DATE:20280715
DTEND;VALUE=DATE:20280716
SUMMARY:Nemluvio (nemolizumab): Phase 2 readout est. (NCT07660835)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 2\, Atopic Dermatitis.\nStudy: P
 harmacokinetics\, Safety and Efficacy of Nemolizumab in Participants Aged 
 6 to 23 Months With Moderate-to Severe Atopic Dermatitis\nEstimated primar
 y completion: 15 July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/nemolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07660835
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
